Form 8-K - Current report:
SEC Accession No. 0001641172-25-017286
Filing Date
2025-07-01
Accepted
2025-07-01 09:00:30
Documents
12
Period of Report
2025-07-01
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 38082
  Complete submission text file 0001641172-25-017286.txt   204501

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE prph-20250701.xsd EX-101.SCH 3026
3 XBRL LABEL FILE prph-20250701_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE prph-20250701_pre.xml EX-101.PRE 22366
14 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3716
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

EIN.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 251094292
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)